1. Home
  2. ONCY

as of 05-19-2026 3:41pm EST

$0.79
$0.01
-1.24%
Stocks Health Care Pharmaceuticals and Biotechnology Nasdaq

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Founded: 1998 Country:
Canada
Canada
Employees: 29 City: SAN DIEGO
Market Cap: 98.7M IPO Year: 2002
Target Price: $7.33 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.30 EPS Growth: N/A
52 Week Low/High: $0.33 - $1.51 Next Earning Date: 05-08-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 2505.00%
P/E Ratio: -2.67 Index: N/A
Free Cash Flow: -20118000.0 FCF Growth: N/A

AI-Powered ONCY Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 71.26%
71.26%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Oncolytics Biotech Inc. (ONCY)

Kelly Jared

Chief Executive Officer

Buy
ONCY Mar 12, 2026

Avg Cost/Share

$0.96

Shares

5,050

Total Value

$4,848.00

Owned After

114,050

SEC Form 4

Buy
ONCY Mar 11, 2026

Avg Cost/Share

$1.03

Shares

10,000

Total Value

$10,300.00

Owned After

41,849

SEC Form 4

Share on Social Networks: